The FDA has not reviewed or approved concurrent use of these agents, and compounding pharmacies operate within state regulations that require clinical oversight
Kosiborod reports having served as a consultant or as an advisory board member for 35Pharma, Alnylam, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, and Youngene Therapeutics
AOD 9604 does not suppress appetite the way GLP-1 medications do
The risk of DKA does not appear to be elevated with GLP-1 drugs in T1D a meaningful distinction from SGLT2 inhibitors
It is not only a good helper for the preparation of injectable drugs, but also a guardian ensuring the safe use of drugs
This matters even more for people also using drugs similar to semaglutide